Article Text

Download PDFPDF
Novel patient-specific visual analogue survey (PVS) is validated in patients treated with collagenase injection for Dupuytren’s disease
  1. Stephen L Lyman1,
  2. Jayme Burket Kotsov2,
  3. Chisa Hidaka1,
  4. Quynh Tran3,
  5. Naomi Roselaar1,
  6. Norimasa Nakamura4,5,
  7. Robert Hotchkiss3
  1. 1Healthcare Research Institute, Hospital for Special Surgery, New York, New York, USA
  2. 2Department of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, California, USA
  3. 3Hand and Upper Extremity, Hospital for Special Surgery, New York, New York, USA
  4. 4Department Orthopaedic Surgery, Institute of Sports Science, Center for Advanced Medical Engineering and Informatics, Osaka University, Suita, Japan
  5. 5Institute for Medical Science in Sports, Osaka Health Science University, Osaka, Japan
  1. Correspondence to Dr Stephen L Lyman, Healthcare Research Institute, Hospital for Special Surgery, New York, NY 10021, USA; lymans{at}hss.edu

Abstract

Objectives We developed and validated an electronically administered patient-specific visual analogue survey (PVS) to evaluate changes in hand function after treatment with injectable collagenase clostridium histolyticum (CCH) in Dupuytren’s contracture. The items in the PVS were authored and ranked in importance by the patients.

Methods In an open-label trial for patients with Dupuytren’s contracture receiving CCH injection, 109 patients completed the PVS on the day of injection, day of manipulation and 30-day follow-up. For external validation, patients also completed standard patient-reported outcome measures, the Overall Treatment Effects Scale and QuickDASH, and underwent physician assessment of contracture via goniometry and the table top test.

Results Responses were highly individualised with no single activity being chosen as important by more than 8% of patients. Sports-related activities were mentioned most often (23%). The PVS was highly responsive to changes in patients’ conditions with CCH injection (effect size=1.49), much more so than the QuickDASH (effect size=0.50). Additionally, the PVS had no floor or ceiling effects, whereas the QuickDASH ceiling approached 20% post-injection. The PVS had excellent internal consistency (Cronbach’s α=0.95) and correlated strongly with the QuickDASH post-injection (Spearman’s=−0.67). PVS scores were significantly higher for patients reporting their condition had improved versus those reporting no change after injection. The test–retest reliability of the PVS was poor to fair, in part due to allowing patients to choose different activities at test and retest. However, test–retest reliability was good (intraclass correlation coefficient >0.7) and better than QuickDASH among patients who rated the same activities at test and retest.

Conclusions The PVS is simple to administer and enables individualised assessment in a large number of patients. It is also readily adaptable for use in other diseases, particularly within musculoskeletal medicine.

Level of evidence Therapeutic II: Prospective cohort.

  • Hand
  • Stiff Joints
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors Study design: SLL, RH, QT, JBK. Patient recruitment: RH, QT. Data collection: QT, NR. Statistical analysis: SLL, JBK, RH. Results interpretation: RH, JBK, SLL, CH, NN. Manuscript preparation: SLL, RH, QT, JBK, NR, CH, NN.

  • Funding This study was funded by Auxilium Pharmaceuticals.

  • Competing interests QT reports grants from Auxilium Pharmaceuticals during the conduct of the study. SLL reports compensation from OMNI, JOSCAS and Universal Research Solutions. He also reports his position as the statistics editor for the Journal of Bone and Joint Surgery.

  • Patient consent for publication Not required.

  • Ethics approval The trial was approved by our Institutional Review Board (IRB no. 2013-067).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.